Expanding the Abu Dhabi Bone Marrow Transplant Program (AD-BMT<sup>®</sup>) Scope with the Collection and Cryopreservation of Cord Blood Stem Cells

Rene Antonio Rivero-Jimenez; Antonio Alfonso Bencomo-Hernandez; Yandy Marx Castillo-Aleman; Fatema Mohammed Al Kaabi; Yendry Ventura-Carmenate

doi:doi:10.11648/j.cmr.20231202.12

Expanding the Abu Dhabi Bone Marrow Transplant Program (AD-BMT^®) Scope with the Collection and Cryopreservation of Cord Blood Stem Cells

Rene Antonio Rivero-Jimenez, Antonio Alfonso Bencomo-Hernandez, Yandy Marx Castillo-Aleman, Fatema Mohammed Al Kaabi, Yendry Ventura-Carmenate

Published in Clinical Medicine Research (Volume 12, Issue 2)

Received: 12 April 2023 Accepted: 27 April 2023 Published: 10 May 2023

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Introduction: The umbilical cord blood (UCB) is the blood from the placenta's blood vessels and the portion of the umbilical cord that remains attached to the newborn after the delivery when the cord is clamped and cut. UCB is rich in hematopoietic stem cells (HSC) and other stem cells (SC). Between 1974 and 1988, scientific knowledge and UCB application possibilities for human therapy opened a new significative era in cell therapy, using UCB HSC as an alternative source of SC for bone marrow transplant and the cure of patients with malignant hematological diseases. Objective: The possibility of having a UCB bank (UCB-B) in Abu Dhabi encouraged us to make this analysis. Method: A literature review from Google Scholar, PubMed, SciELO, Scopus, and other sources, about the increasing application of UCB-SC and storage in UCB-B was done to update about all the possibilities for translational medicine. Results: We prepared a UCB overview, including the pioneering use of UCB-SC for HSC transplantation, their biological composition, characteristics, and the UC-associated tissues like Wharton-Jelly and the human term placenta, UCB advantages, and disadvantages in HSC transplantation, the number of clinical trials applying UCB donation samples, and promising possibilities for regenerative medicine. The existence of different types of UCB-Bs, and the development of new specific cellular manipulation techniques. The UCB-B regulatory framework and some ethical issues were also included in the review. Conclusions: After 30 years of UCB-B, more than 100 public UCB-Bs worldwide, with millions of UCB units donated altruistically, more than 800,000 clinical-grade products are now available: a great source of transplantable SC and other cellular material for the development of new therapies. Even though the UCB as a source of HSC for transplantation has been recently statistical ranked in third place, after HSC apheresis collected and bone marrow aspirates, until now, more than 50,000 UCB HSC allogeneic transplants (HSC-Allo-T) have been performed worldwide in both children and adults to treat many different diseases, including hematologic, metabolic, immunologic, neoplastic, and neurologic disorders. A significant effort has been focused on enhancing engraftment to reduce the risk of infection and cost. Recommendations: To that end, we must understand in detail the molecular mechanisms controlling SC self-renewal that may lead to the development of ex-vivo systems for HSCs expansion, characterize the mechanisms regulating the homing of HSC and determine the relative place of UCB HSC-Allo-T, as compared to other sources.

Published in	Clinical Medicine Research (Volume 12, Issue 2)
DOI	10.11648/j.cmr.20231202.12
Page(s)	30-47
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Transplant, Blood, Umbilical Cord, Histocompatibility, Stem Cells, Regenerative Medicine, HLA

References

[1]	World Bone Marrow Donors Association (WMDA). (2022). The Netherlands. Bone Marrow Donors Database [Internet]. [cited 2023 Jan 10]. Available from: https://statistics.wmda.info/
[2]	New York Blood Center Enterprises. (2022). Cell Therapy. Unparalleled Access to a Broad Range of Cellular Products. https://www.nybce.org/blood-products-services/cell-therapies/.
[3]	Waller-Wise R. (2011). Umbilical Cord Blood: Information for Childbirth Educators. J Perinat Educ. 20 (1): 54–60. DOI: 10.1891/1058-1243.20.1.54.
[4]	Knudtzon S. (1974). In vitro growth of granulocytic colonies from circulating cells in human cord blood. Blood. 43 (3): 357–61.
[5]	Nakahata T, Ogawa M. (1982). Hemopoietic colony-forming cells in umbilical cord blood with extensive capability to generate mono- and multipotential hemopoietic progenitors. Journal of Clinical Investigation. 1; 70 (6): 1324–8. DOI: 10.1172/JCI110734.
[6]	Gluckman E, Broxmeyer HE, Auerbach AD, Friedman HS, Douglas GW, Devergie A, et al. (1989). Hematopoietic Reconstitution in a Patient with Fanconi's Anemia by Means of Umbilical-Cord Blood from an HLA-Identical Sibling. New England Journal of Medicine. 321 (17): 1174–8. DOI: 10.1056/NEJM198910263211707.
[7]	Gluckman E. (2000). Current status of umbilical cord blood hematopoietic stem cell transplantation. Exp Hematol. 28 (11): 1197–205. DOI: 10.1016/S0301-472X(00)00540-3.
[8]	Munoz J, Shah N, Rezvani K, Hosing C, Bollard CM, Oran B, et al. (2014). Concise Review: Umbilical Cord Blood Transplantation: Past, Present, and Future. Stem Cells Transl Med. 3 (12): 1435–43. DOI: 10.5966/sctm.2014-0151.
[9]	Garcia Lopez J. (2005). Current situation of umbilical cord blood banks and their therapeutic utility [Situación actual de los bancos de sangre de cordón umbilical y su utilidad terapéutica]. [Internet]. Acta Cient Tecnol. [cited 2023 Jan 11]. p. 37–9. Available from: https://www.aecientificos.es/wp-content/uploads/2019/10/09-Revista- AEC.pdf
[10]	Smith AR, Wagner JE. (2009). Alternative haematopoietic stem cell sources for transplantation: place of umbilical cord blood. Br J Haematol. 147 (2): 246– 61. DOI: 10.1111/j.1365-2141.2009.07828.x.
[11]	Basmaeil YS, Al Subayyil AM, Khatlani T, Bahattab E, Al-Alwan M, Abomaray FM, et al. Human chorionic villous mesenchymal stem/stromal cells protect endothelial cells from injury induced by high level of glucose. Stem Cell Res Ther. 2018 Dec 21; 9 (1): 238. DOI: 10.1186/s13287-018-0984-0.
[12]	Teofili L, Silini AR, Bianchi M, Valentini CG, Parolini O. (2018). Incorporating placental tissue in cord blood banking for stem cell transplantation. Expert Rev Hematol. 11 (8): 649–61. DOI: 10.1080/17474086.2018.1483717.
[13]	Sirchia G, Rebulla P, Mozzi F, Lecchi L, Lazzari L, Ratti I. (1998). A quality system for placental blood banking. Bone Marrow Transplant. Suppl 3: S43–7.
[14]	Morera-Barrios Luz, Jaime-Fagundo Juan Carlos, Dorticós-Balea Elvira, Ustáriz-García Catalino, Hernández-Ramírez Porfirio. Hematopoietic Stem Cells from Umbilical Cord Blood [Células progenitoras hematopoyéticas de sangre de cordón umbilical] (2012). [Internet]. Rev Cubana Hematol Inmunol Hemoter [online]. [cited 2023 Jan 11]. p. 130–40. Available from: .
[15]	Troyer DL, Weiss ML. (2008). Concise Review: Wharton's Jelly-Derived Cells Are a Primitive Stromal Cell Population. Stem Cells. 26 (3): 591–9. DOI: 10.1634/stemcells.2007-0439.
[16]	Fong CY, Chak LL, Biswas A, Tan JH, Gauthaman K, Chan WK, et al. (2011). Human Wharton's Jelly Stem Cells Have Unique Transcriptome Profiles Compared to Human Embryonic Stem Cells and Other Mesenchymal Stem Cells. Stem Cell Rev Rep. 7 (1): 1–16. DOI: 10.1007/s12015-010-9166-x.
[17]	El Omar R, Beroud J, Stoltz JF, Menu P, Velot E, Decot V. (2014). Umbilical Cord Mesenchymal Stem Cells: The New Gold Standard for Mesenchymal Stem Cell- Based Therapies? Tissue Eng Part B Rev. 20 (5): 523–44. DOI: 10.1089/ten.teb.2013.0664.
[18]	Gauthaman K, Fong CY, Suganya CA, Subramanian A, Biswas A, Choolani M, et al. (2012). Extra-embryonic human Wharton's jelly stem cells do not induce tumorigenesis, unlike human embryonic stem cells. Reprod Biomed Online. 24 (2): 235–46. DOI: 10.1016/j.rbmo.2011.10.007.
[19]	Barrett AN, Fong CY, Subramanian A, Liu W, Feng Y, Choolani M, et al. (2019). Human Wharton's Jelly Mesenchymal Stem Cells Show Unique Gene Expression Compared with Bone Marrow Mesenchymal Stem Cells Using Single-Cell RNA-Sequencing. Stem Cells Dev. 28 (3): 196–211. DOI: 10.1089/scd.2018.0132.
[20]	Hass R, Kasper C, Böhm S, Jacobs R. (2011). Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. Cell Communication and Signaling. 9 (1): 12. DOI: 10.1186/1478-811X-9-12.
[21]	La Rocca G, Anzalone R, Corrao S, Magno F, Loria T, lo Iacono M, et al. (2009). Isolation and characterization of Oct-4+/HLA-G+ mesenchymal stem cells from human umbilical cord matrix: differentiation potential and detection of new markers. Histochem Cell Biol. 131 (2): 267–82. DOI: 10.1007/s00418-008-0519-3.
[22]	Min K, Song J, Kang JY, Ko J, Ryu JS, Kang MS, et al. (2013). Umbilical Cord Blood Therapy Potentiated with Erythropoietin for Children with Cerebral Palsy: A Double-blind, Randomized, Placebo-Controlled Trial. Stem Cells. 31 (3): 581–91. DOI: 10.1002/stem.1304.
[23]	Dewan S, Schimmel S, Borlongan C V. (2018). Treating childhood traumatic brain injury with autologous stem cell therapy. Expert Opin Biol Ther. 18 (5): 515–24. DOI: 10.1080/14712598.2018.1439473.
[24]	Sun J, Allison J, McLaughlin C, Sledge L, Waters-Pick B, Wease S, et al. (2010). Differences in quality between privately and publicly banked umbilical cord blood units: a pilot study of autologous cord blood infusion in children with acquired neurologic disorders. Transfusion (Paris). 50 (9): 1980–7. DOI: 10.1111/j.1537-2995.2010.02720.x.
[25]	Reddi A, Kothari N, Kuppasani K, Ende N. (2015). Human Umbilical Cord Blood Cells and Diabetes Mellitus: Recent Advances. Curr Stem Cell Res Ther. 10 (3): 266–70. DOI: 10.2174/1574888X10666141212122421.
[26]	Greco N, Laughlin MJ. (2010). Umbilical Cord Blood Stem Cells for Myocardial Repair and Regeneration. p. 29–52. DOI: 10.1007/978-1-60761-705-1_3.
[27]	Reza HM, Ng BY, Gimeno FL, Phan TT, Ang LPK. (2011). Umbilical Cord Lining Stem Cells as a Novel and Promising Source for Ocular Surface Regeneration. Stem Cell Rev Rep. 7 (4): 935–47. DOI: 10.1007/s12015-011-9245-7.
[28]	Giannaccare G, Carnevali A, Senni C, Logozzo L, Scorcia V. (2020). Umbilical Cord Blood and Serum for the Treatment of Ocular Diseases: A Comprehensive Review. Ophthalmol Ther. 9 (2): 235–48. DOI: 10.1007/s40123-020-00239-9.
[29]	Abumaree MH, Hakami M, Abomaray FM, Alshabibi MA, Kalionis B, al Jumah MA, et al. (2017). Human chorionic villous mesenchymal stem/stromal cells modify the effects of oxidative stress on endothelial cell functions. Placenta. 59: 74–86. DOI: 10.1016/j.placenta.2017.05.001.
[30]	Oh IH, Lau A, Eaves CJ. (2020). During ontogeny primitive (CD34(+)CD38(-)) hematopoietic cells show altered expression of a subset of genes associated with early cytokine and differentiation responses of their adult counterparts. Blood. 96 (13): 4160–6.
[31]	Szilvassy SJ, Meyerrose TE, Ragland PL, Grimes B. (2001). Differential homing and engraftment properties of hematopoietic progenitor cells from murine bone marrow, mobilized peripheral blood, and fetal liver. Blood. 98 (7): 2108–15. DOI: 10.1182/blood.V98.7.2108.
[32]	Rosler ES, Brand JE, Chute J, Hoffman R. (2000). An in vivo competitive repopulation assay for various sources of human hematopoietic stem cells. Blood. 96 (10): 3414–21.
[33]	Ballen KK, Spitzer TR. (2011). The great debate: haploidentical or cord blood transplant. Bone Marrow Transplant. 46 (3): 323–9. DOI: 10.1038/bmt.2010.260.
[34]	Querol S, Rubinstein P, Marsh SGE, Goldman J, Madrigal JA. (2009). Cord blood banking: 'providing cord blood banking for a nation.' Br J Haematol. 147 (2): 227–35. DOI: 10.1111/j.1365-2141.2009.07818.x.
[35]	Barker JN, Byam CE, Kernan NA, Lee SS, Hawke RM, Doshi KA, et al. (2010). Availability of Cord Blood Extends Allogeneic Hematopoietic Stem Cell Transplant Access to Racial and Ethnic Minorities. Biology of Blood and Marrow Transplantation. 16 (11): 1541–8. DOI: 10.1016/j.bbmt.2010.08.011.
[36]	Cuende N, Rasko JEJ, Koh MBC, Dominici M, Ikonomou L. (2018). Cell, tissue and gene products with marketing authorization in 2018 worldwide. Cytotherapy. 20 (11): 1401–13. DOI: 10.1016/j.jcyt.2018.09.010.
[37]	Cohen YC, Scaradavou A, Stevens CE, Rubinstein P, Gluckman E, Rocha V, et al. (2011). Factors affecting mortality following myeloablative cord blood transplantation in adults: a pooled analysis of three international registries. Bone Marrow Transplant. 46 (1): 70–6. DOI: 10.1038/bmt.2010.83.
[38]	Mehta RS, Rezvani K, Olson A, Oran B, Hosing C, Shah N, et al. (2015). Novel Techniques for Ex Vivo Expansion of Cord Blood: Clinical Trials. Front Med (Lausanne). 2. DOI: 10.3389/fmed.2015.00089.
[39]	Rivero-Jiménez RA. (2008). Review article: Ex-vivo expansion cultures of Stem Cells from Umbilical Cord Blood [Articulo de revision: cultivos de expansión ex vivo de células madre a partir de sangre de cordón umbilical]. Rev Argent Transfus ; 34 (1 / 2): 71-8+.
[40]	Ballen KK, Koreth J, Chen YB, Dey BR, Spitzer TR. (2012). Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant. Blood. 119 (9): 1972–80. DOI: 10.1182/blood-2011-11-354563.
[41]	Parent's Guide to Cord Blood Foundation. (2023). Recruiting Trials: Cord Blood [Internet]. [cited 2023 Jan 12]. Available from: https://parentsguidecordblood.org/en/trials
[42]	Abumaree MH, al Jumah MA, Kalionis B, Jawdat D, Al Khaldi A, Al Talabani AA, et al. (2013). Phenotypic and Functional Characterization of Mesenchymal Stem Cells from Chorionic Villi of Human Term Placenta. Stem Cell Rev Rep. 9 (1): 16–31. DOI: 10.1007/s12015-012-9385-4.
[43]	Abumaree MH, al Jumah MA, Kalionis B, Jawdat D, al Khaldi A, Abomaray FM, et al. (2013) Human Placental Mesenchymal Stem Cells (pMSCs) Play a Role as Immune Suppressive Cells by Shifting Macrophage Differentiation from Inflammatory M1 to Anti-inflammatory M2 Macrophages. Stem Cell Rev Rep. 9 (5): 620–41. DOI: 10.1007/s12015-013-9455-2.
[44]	Ghareeb AE, Lako M, Figueiredo FC. Recent Advances in Stem Cell Therapy for Limbal Stem Cell Deficiency: A Narrative Review. Ophthalmol Ther. 2020 Dec 24; 9 (4): 809–31. DOI: 10.1007/s40123-020-00305-2.
[45]	Li Y, Hao J, Hu Z, Yang YG, Zhou Q, Sun L, et al. (2022). Current status of clinical trials assessing mesenchymal stem cell therapy for graft versus host disease: a systematic review. Stem Cell Res Ther. 13 (1): 93. DOI: 10.1186/s13287-022-02751-0.
[46]	Rivero-Jimenez RA. (2014). Reasons for a cord blood bank at the Institute of Hematology and Immunology, Cuba. [Razones para un banco de sangre de cordón umbilical en el Instituto de Hematología e Inmunología de Cuba]. [Internet]. Rev Cubana Hematol Inmunol Hemoter [online]. [cited 2023 Jan 11]. p. 4–10. Available from:.
[47]	Breier DV, Querol S, Garcia J. (2006). Therapeutic alternatives in post-transplantation: Specific adoptive immunotherapy of umbilical cord blood (UCS) in post- transplantation of hematopoietic progenitor cells [Alternativas terapéuticas en el post transplante: Inmunoterapia adoptiva especifica. Acta Científica y Tecnológica [Internet]. [cited 2023 Jan 11]; 11: 30–2. Available from: https://www.aecientificos.es/wp-content/uploads/2019/10/11-Revista-AEC.pdf
[48]	Shpall EJ, Quinones R, Giller R, Zeng C, Baron AE, Jones RB, et al. (2002). Transplantation of ex vivo expanded cord blood. Biology of Blood and Marrow Transplantation. 8 (7): 368–76. DOI: 10.1053/bbmt.2002.v8.pm12171483.
[49]	Jaroscak J, Goltry K, Smith A, Waters-Pick B, Martin PL, Driscoll TA, et al. Augmentation of umbilical cord blood (UCB) transplantation with ex vivo–expanded UCB cells: results of a phase 1 trial using the AastromReplicell System. Blood. 2003 Jun 15; 101 (12): 5061–7. DOI: 10.1182/blood-2001-12-0290.
[50]	Petz LD, Redei I, Bryson Y, Regan D, Kurtzberg J, Shpall E, et al. (2013). Hematopoietic Cell Transplantation with Cord Blood for Cure of HIV Infections. Biology of Blood and Marrow Transplantation. 19 (3): 393–7. DOI: 10.1016/j.bbmt.2012.10.017.
[51]	Marley G, Tan RKJ, Tang W. (2022). Stem cell research finds possible HIV cure with cord blood transplant. The Innovation. 3 (3): 100238. DOI: 10.1016/j.xinn.2022.100238.
[52]	Querol S. (2012). Cord blood banking: current status. Hematology. 17 (sup1): s185–8. DOI: 10.1179/102453312X13336169157013.
[53]	US Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. Biologics License Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System. FDA. Guidance for Industry. 2014. p. 1–48.
[54]	Dehn J, Spellman S, Hurley CK, Shaw BE, Barker JN, Burns LJ, et al. (2019). Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR. Blood. 134 (12): 924–34. DOI: 10.1182/blood.2019001212. Epub 2019 Jul 10.
[55]	Bart T, Boo M, Balabanova S, Fischer Y, Nicoloso G, Foeken L, et al. Impact of Selection of Cord Blood Units from the United States and Swiss Registries on the Cost of Banking Operations. Transfusion Medicine and Hemotherapy. 2013; 40 (1): 14– 20. DOI: 10.1159/000345690.
[56]	FACT- JACIE – Foundation for the Accreditation of Cellular Therapy/Join Accreditation Committee ISCT-EBMT. (2021). International Standards for the Collection, Processing, and Administration of Hematopoietic Cell Therapy Products [Internet]. International Standards FACT-JACIE Eight Edition – Version 8.0. [cited 2023 Jan 12]. p. 1–156. Available from: https://www.ebmt.org/sites/default/files/2021-08/Est%C3%A1ndares%20Internacionales%20FACT- JACIE%20Octava%20Edicion%20Completa.pdf
[57]	Rubinstein P. (2009). Cord blood banking for clinical transplantation. Bone Marrow Transplant. 44 (10): 635–42. DOI: 10.1038/bmt.2009.281.
[58]	Armitage S. (2016). Cord Blood Banking Standards: Autologous Versus Altruistic. Front Med (Lausanne). 2. DOI: 10.3389/fmed.2015.00094. DOI: 10.3747/co.v18i3.742.
[59]	Royal College of Gynecology. (2006). Umbilical Cord Blood Banking (Scientific Impact Paper No. 2) [Internet]. Opinion Paper 2. 2006 [cited 2023 Jan 11]. Available from: https://www.rcog.org.uk/media/24pjeoia/sip_2.pdf
[60]	Gassas A. (2011). Cord Stem-Cell Transplantation in Ontario: Do We Need a Public Bank? Current Oncology. 18 (3): 121–5. DOI: 10.3747/co.v18i3.742.
[61]	PAHO/WHO. (2013). Legislation on organ, tissue and cell donation and transplantation: compilation and comparative analysis [Legislación sobre donación y trasplante de órganos, tejidos y células: compilación y análisis comparado] [Internet]. [cited 2023 Jan 11]. Available from: https://www3.paho.org/hq/index.php?option=com_content&view=article&id=8473:2013-legislacion-donacion-trasplante-organos-tejidos-celulas-compilacion-analisis-comparado&Itemid=0&lang=en#gsc.tab=0
[62]	WHO. (2010). Sixty-Third World Health Assembly. Human and Organ Tissue Transplantation. WHA63.22. [cited 2023 Jan 11]; Available from: https://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_R22-en.pdf?ua=1
[63]	Council of Europe. (2016). Umbilical cord blood banking. A guide for parents [Internet]. 2nd Edition. [cited 2023 Jan 11]. Available from: https://www.edqm.eu/documents/52006/75920/umbilical-cord-blood-banking-2nd-edition-2016-0.pdf/5aee269d-477a-6d4c-f07a-b196bb72cf37?t=1623404919424
[64]	American Academy of Pediatrics. Section on Hematology/Oncology, American Academy of Pediatrics Section on Allergy/Immunology; Bertram H Lubin WTS. (2007). Cord Blood Banking for Potential Future Transplantation. Pediatrics. 119 (1): 165–70. DOI: 10.1542/peds.2006-2901.
[65]	Parent's Guide to Cord Blood Foundation. (2023). World Map Family Banks [Internet]. [cited 2023 Jan 12]. Available from: https://parentsguidecordblood.org/en/family- banking-world-map
[66]	Querol S, Gomez SG, Pagliuca A, Torrabadella M, Madrigal JA. (2010). Quality rather than quantity: the cord blood bank dilemma. Bone Marrow Transplant. 45 (6): 970–8. DOI: 10.1038/bmt.2010.7.
[67]	World Marrow Donor Association (WMDA). (2021). 2021 WMDA Finances and Activities Report. [Internet]. https://wmda.info/wp-content/uploads/2022/05/WMDA-Finance- Activities-Report-2021-gecomprimeerd.pdf. [cited 2023 Feb 27]. p. 1–28. Available from: https://wmda.info/wp-content/uploads/2022/05/WMDA-Finance- Activities-Report-2021-gecomprimeerd.pdf
[68]	Querol S, Rubinstein P, Madrigal A. (2021). The wider perspective: cord blood banks and their future prospects. Br J Haematol. 195 (4): 507–17. DOI: 10.1111/bjh.17468.
[69]	Petrini C. (2010). Umbilical cord blood collection, storage and use: ethical issues. Blood Transfus. 8 (3): 139–48. DOI: 10.2450/2010.0152-09.
[70]	Querol S. (2003). “Ex vivo” cryopreservation and expansion of hematopoietic progenitors from umbilical cord blood and amniotic tissue for unrelated transplants: III. Quality indicators in the cordon bank. [Criopreservación y expansión “ex vivo” de progenitores hematopoyéticos de sangre de cordón umbilical y tejido amniótico para trasplantes no relacionados: III. Indicadores de calidad en el banco de cordón]. Gac Méd Méx. 139 (Suppl 3): S98–101.
[71]	Gluckman E, Ruggeri A, Rocha V, Baudoux E, Boo M, Kurtzberg J, et al. (2011). Family- directed umbilical cord blood banking. Haematologica. 96 (11): 1700–7. DOI: 10.3324/haematol.2011.047050.
[72]	Sirchia G, Rebulla P, Tibaldi S, Lecchi L. (1999). Cost of umbilical cord blood units released for transplantation. Transfusion (Paris). 39 (6): 645–50. DOI: 10.1046/j.1537-2995.1999.39060645.x.
[73]	NetCord-FACT (The Foundation for the Accreditation of Cellular Therapy). (2019). International Standards for Cord Blood Collection. Seventh Edition, Banking, and Release for Administration. https://fact.policytech.com/dotNet/documents/?docid=229&public=true. p. 1– 103.
[74]	US Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. (2022). Regulation of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). Small Entity Compliance Guide. [Internet]. FDA Guidance for Industry. [cited 2023 Jan 12]. p. 1–18. Available from: https://www.fda.gov/media/70689/download
[75]	US National Archives and Records. Code of Regulations. (2023). Title 21 of the CFR (eCFR version) [Internet]. Chapter I Food and Drug Administration, Department of Health and Human Services. [cited 2023 Jan 12]. p. 1–1299. Available from: https://www.ecfr.gov/current/title-21
[76]	US Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. (2014). Biologics License Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System. FDA. Guidance for Industry. p. 1–48.
[77]	Petrini C. (2012). European regulations on cord blood banking: an overview. Transfusion (Paris). 52 (3): 668–79. DOI: 10.1111/j.1537-2995.2011.03257.x.
[78]	Abu Dhabi Department of Health (DOH). (2019). DOH Standard on Stem Cell Therapies, Products & Regenerative Medicine [Internet]. Document Ref. Number: DOH/QD/SD/STCT/0.9 Version: 0.9. [cited 2023 Jan 17]. p. 1–20. Available from: file:///C:/Users/Hp/Downloads/DOH%20STANDARD%20ON%20STEM%20CELL%20 THERAPIES%20AND%20PRODUCTS%20%20REGENERATIVE%20MEDICINE%20(5).pdf
[79]	Abu Dhabi Department of Health (DOH). (2019). DOH Standard for Center of Excellence in Hematopoietic Stem Cell Transplantation (HSCT) Services for Adults and Pediatrics [Internet]. Document type Standard Document Ref. Number: DOH/HPI/COEHSCT/0.9/2019. [cited 2023 Jan 17]. p. 1–7. Available from: file:///C:/Users/Hp/Downloads/20191125DOH%20STANDARD%20FOR%20COE%20I N%20HEMATOPOIETIC%20STEM%20CELL%20TRANSPLANTATION%20HSCT% 20(2).pdf
[80]	AABB (Association for the Advancement of Blood & Biotherapies). (2023). Cellular Therapy Facilities. Cord Blood Banks. [Internet]. www.aabb.org. [cited 2023 Mar 21]. Available from: https://www.aabb.org/standards-accreditation/accreditation/accredited-facilities/cellular-therapy-facilities
[81]	Ellenchild Pinch W.J. (2001). Cord Blood Banking: Ethical Implications: It offers hope, but proceed with caution. American Journal of Nursing. 101 (10): 55–9.
[82]	Bhandari R, Lindley A, Bhatla D, Babic A, Mueckl K, Rao R, et al. (2017). Awareness of cord blood collection and the impact on banking. Pediatr Blood Cancer. 64 (7): e26412. DOI: 10.1002/pbc.26412.
[83]	Gluckman E. (2000). Ethical and legal aspects of placental/cord blood banking and transplant. The Hematology Journal. 1 (1): 67–9. DOI: 10.1038/sj.thj.6200010.
[84]	Mayani H, Wagner JE, Broxmeyer HE. (2020). Cord blood research, banking, and transplantation: achievements, challenges, and perspectives. Bone Marrow Transplant. 55 (1): 48–61. DOI: 10.1038/s41409-019-0546-9.
[85]	US Food and Drug Administration (FDA). (2023). FDA Approves Cell Therapy for Patients with Blood Cancers to Reduce Risk of Infection Following Stem Cell Transplantation. News Release. Announced 2023-04-17.
[86]	US Food and Drug Administration (FDA). (2023) BLA Approval Letter to Gamida Cell. Released 2023-04-17.
[87]	Verter F. (2023). 1st. FDA Approval Omisirge Expanded Cord Blood. Parent's Guide to Cord Blood Foundation, News published 2023-04. Available from: https://parentsguidecordblood.org/en/news/1st-fda-approval-omisirge-expanded-cord-blood

Cite This Article

Plain Text BibTeX RIS

APA Style

Rene Antonio Rivero-Jimenez, Antonio Alfonso Bencomo-Hernandez, Yandy Marx Castillo-Aleman, Fatema Mohammed Al Kaabi, Yendry Ventura-Carmenate. (2023). Expanding the Abu Dhabi Bone Marrow Transplant Program (AD-BMT®) Scope with the Collection and Cryopreservation of Cord Blood Stem Cells. Clinical Medicine Research, 12(2), 30-47. https://doi.org/10.11648/j.cmr.20231202.12

Copy | Download

ACS Style

Rene Antonio Rivero-Jimenez; Antonio Alfonso Bencomo-Hernandez; Yandy Marx Castillo-Aleman; Fatema Mohammed Al Kaabi; Yendry Ventura-Carmenate. Expanding the Abu Dhabi Bone Marrow Transplant Program (AD-BMT®) Scope with the Collection and Cryopreservation of Cord Blood Stem Cells. Clin. Med. Res. 2023, 12(2), 30-47. doi: 10.11648/j.cmr.20231202.12

Copy | Download

AMA Style

Rene Antonio Rivero-Jimenez, Antonio Alfonso Bencomo-Hernandez, Yandy Marx Castillo-Aleman, Fatema Mohammed Al Kaabi, Yendry Ventura-Carmenate. Expanding the Abu Dhabi Bone Marrow Transplant Program (AD-BMT®) Scope with the Collection and Cryopreservation of Cord Blood Stem Cells. Clin Med Res. 2023;12(2):30-47. doi: 10.11648/j.cmr.20231202.12

Copy | Download

@article{10.11648/j.cmr.20231202.12,
  author = {Rene Antonio Rivero-Jimenez and Antonio Alfonso Bencomo-Hernandez and Yandy Marx Castillo-Aleman and Fatema Mohammed Al Kaabi and Yendry Ventura-Carmenate},
  title = {Expanding the Abu Dhabi Bone Marrow Transplant Program (AD-BMT®) Scope with the Collection and Cryopreservation of Cord Blood Stem Cells},
  journal = {Clinical Medicine Research},
  volume = {12},
  number = {2},
  pages = {30-47},
  doi = {10.11648/j.cmr.20231202.12},
  url = {https://doi.org/10.11648/j.cmr.20231202.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.cmr.20231202.12},
  abstract = {Introduction: The umbilical cord blood (UCB) is the blood from the placenta's blood vessels and the portion of the umbilical cord that remains attached to the newborn after the delivery when the cord is clamped and cut. UCB is rich in hematopoietic stem cells (HSC) and other stem cells (SC). Between 1974 and 1988, scientific knowledge and UCB application possibilities for human therapy opened a new significative era in cell therapy, using UCB HSC as an alternative source of SC for bone marrow transplant and the cure of patients with malignant hematological diseases. Objective: The possibility of having a UCB bank (UCB-B) in Abu Dhabi encouraged us to make this analysis. Method: A literature review from Google Scholar, PubMed, SciELO, Scopus, and other sources, about the increasing application of UCB-SC and storage in UCB-B was done to update about all the possibilities for translational medicine. Results: We prepared a UCB overview, including the pioneering use of UCB-SC for HSC transplantation, their biological composition, characteristics, and the UC-associated tissues like Wharton-Jelly and the human term placenta, UCB advantages, and disadvantages in HSC transplantation, the number of clinical trials applying UCB donation samples, and promising possibilities for regenerative medicine. The existence of different types of UCB-Bs, and the development of new specific cellular manipulation techniques. The UCB-B regulatory framework and some ethical issues were also included in the review. Conclusions: After 30 years of UCB-B, more than 100 public UCB-Bs worldwide, with millions of UCB units donated altruistically, more than 800,000 clinical-grade products are now available: a great source of transplantable SC and other cellular material for the development of new therapies. Even though the UCB as a source of HSC for transplantation has been recently statistical ranked in third place, after HSC apheresis collected and bone marrow aspirates, until now, more than 50,000 UCB HSC allogeneic transplants (HSC-Allo-T) have been performed worldwide in both children and adults to treat many different diseases, including hematologic, metabolic, immunologic, neoplastic, and neurologic disorders. A significant effort has been focused on enhancing engraftment to reduce the risk of infection and cost. Recommendations: To that end, we must understand in detail the molecular mechanisms controlling SC self-renewal that may lead to the development of ex-vivo systems for HSCs expansion, characterize the mechanisms regulating the homing of HSC and determine the relative place of UCB HSC-Allo-T, as compared to other sources.},
 year = {2023}
}

Copy | Download

TY  - JOUR
T1  - Expanding the Abu Dhabi Bone Marrow Transplant Program (AD-BMT®) Scope with the Collection and Cryopreservation of Cord Blood Stem Cells
AU  - Rene Antonio Rivero-Jimenez
AU  - Antonio Alfonso Bencomo-Hernandez
AU  - Yandy Marx Castillo-Aleman
AU  - Fatema Mohammed Al Kaabi
AU  - Yendry Ventura-Carmenate
Y1  - 2023/05/10
PY  - 2023
N1  - https://doi.org/10.11648/j.cmr.20231202.12
DO  - 10.11648/j.cmr.20231202.12
T2  - Clinical Medicine Research
JF  - Clinical Medicine Research
JO  - Clinical Medicine Research
SP  - 30
EP  - 47
PB  - Science Publishing Group
SN  - 2326-9057
UR  - https://doi.org/10.11648/j.cmr.20231202.12
AB  - Introduction: The umbilical cord blood (UCB) is the blood from the placenta's blood vessels and the portion of the umbilical cord that remains attached to the newborn after the delivery when the cord is clamped and cut. UCB is rich in hematopoietic stem cells (HSC) and other stem cells (SC). Between 1974 and 1988, scientific knowledge and UCB application possibilities for human therapy opened a new significative era in cell therapy, using UCB HSC as an alternative source of SC for bone marrow transplant and the cure of patients with malignant hematological diseases. Objective: The possibility of having a UCB bank (UCB-B) in Abu Dhabi encouraged us to make this analysis. Method: A literature review from Google Scholar, PubMed, SciELO, Scopus, and other sources, about the increasing application of UCB-SC and storage in UCB-B was done to update about all the possibilities for translational medicine. Results: We prepared a UCB overview, including the pioneering use of UCB-SC for HSC transplantation, their biological composition, characteristics, and the UC-associated tissues like Wharton-Jelly and the human term placenta, UCB advantages, and disadvantages in HSC transplantation, the number of clinical trials applying UCB donation samples, and promising possibilities for regenerative medicine. The existence of different types of UCB-Bs, and the development of new specific cellular manipulation techniques. The UCB-B regulatory framework and some ethical issues were also included in the review. Conclusions: After 30 years of UCB-B, more than 100 public UCB-Bs worldwide, with millions of UCB units donated altruistically, more than 800,000 clinical-grade products are now available: a great source of transplantable SC and other cellular material for the development of new therapies. Even though the UCB as a source of HSC for transplantation has been recently statistical ranked in third place, after HSC apheresis collected and bone marrow aspirates, until now, more than 50,000 UCB HSC allogeneic transplants (HSC-Allo-T) have been performed worldwide in both children and adults to treat many different diseases, including hematologic, metabolic, immunologic, neoplastic, and neurologic disorders. A significant effort has been focused on enhancing engraftment to reduce the risk of infection and cost. Recommendations: To that end, we must understand in detail the molecular mechanisms controlling SC self-renewal that may lead to the development of ex-vivo systems for HSCs expansion, characterize the mechanisms regulating the homing of HSC and determine the relative place of UCB HSC-Allo-T, as compared to other sources.
VL  - 12
IS  - 2
ER  -

Copy | Download

Author Information

Rene Antonio Rivero-Jimenez

Stem Cell Laboratory Department, Abu Dhabi Stem Cells Center (ADSCC), Abu Dhabi, United Arab Emirates
Antonio Alfonso Bencomo-Hernandez

Stem Cell Laboratory Department, Abu Dhabi Stem Cells Center (ADSCC), Abu Dhabi, United Arab Emirates
Yandy Marx Castillo-Aleman

Department of Immunology, ADSCC/Yas Clinic Khalifa City Hospital, Abu Dhabi, United Arab Emirates
Fatema Mohammed Al Kaabi

Abu Dhabi Bone Marrow Program (AD-BMT^?), ADSCC/Yas Clinic Khalifa City Hospital, Abu Dhabi, United Arab Emirates
Yendry Ventura-Carmenate

AD-BMT^?, ADSCC/Yas Clinic Khalifa City Hospital, Abu Dhabi, United Arab Emirates

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Rene Antonio Rivero-Jimenez, Antonio Alfonso Bencomo-Hernandez, Yandy Marx Castillo-Aleman, Fatema Mohammed Al Kaabi, Yendry Ventura-Carmenate. (2023). Expanding the Abu Dhabi Bone Marrow Transplant Program (AD-BMT®) Scope with the Collection and Cryopreservation of Cord Blood Stem Cells. Clinical Medicine Research, 12(2), 30-47. https://doi.org/10.11648/j.cmr.20231202.12

Copy | Download

ACS Style

Rene Antonio Rivero-Jimenez; Antonio Alfonso Bencomo-Hernandez; Yandy Marx Castillo-Aleman; Fatema Mohammed Al Kaabi; Yendry Ventura-Carmenate. Expanding the Abu Dhabi Bone Marrow Transplant Program (AD-BMT®) Scope with the Collection and Cryopreservation of Cord Blood Stem Cells. Clin. Med. Res. 2023, 12(2), 30-47. doi: 10.11648/j.cmr.20231202.12

Copy | Download

AMA Style

Rene Antonio Rivero-Jimenez, Antonio Alfonso Bencomo-Hernandez, Yandy Marx Castillo-Aleman, Fatema Mohammed Al Kaabi, Yendry Ventura-Carmenate. Expanding the Abu Dhabi Bone Marrow Transplant Program (AD-BMT®) Scope with the Collection and Cryopreservation of Cord Blood Stem Cells. Clin Med Res. 2023;12(2):30-47. doi: 10.11648/j.cmr.20231202.12

Copy | Download

@article{10.11648/j.cmr.20231202.12,
  author = {Rene Antonio Rivero-Jimenez and Antonio Alfonso Bencomo-Hernandez and Yandy Marx Castillo-Aleman and Fatema Mohammed Al Kaabi and Yendry Ventura-Carmenate},
  title = {Expanding the Abu Dhabi Bone Marrow Transplant Program (AD-BMT®) Scope with the Collection and Cryopreservation of Cord Blood Stem Cells},
  journal = {Clinical Medicine Research},
  volume = {12},
  number = {2},
  pages = {30-47},
  doi = {10.11648/j.cmr.20231202.12},
  url = {https://doi.org/10.11648/j.cmr.20231202.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.cmr.20231202.12},
  abstract = {Introduction: The umbilical cord blood (UCB) is the blood from the placenta's blood vessels and the portion of the umbilical cord that remains attached to the newborn after the delivery when the cord is clamped and cut. UCB is rich in hematopoietic stem cells (HSC) and other stem cells (SC). Between 1974 and 1988, scientific knowledge and UCB application possibilities for human therapy opened a new significative era in cell therapy, using UCB HSC as an alternative source of SC for bone marrow transplant and the cure of patients with malignant hematological diseases. Objective: The possibility of having a UCB bank (UCB-B) in Abu Dhabi encouraged us to make this analysis. Method: A literature review from Google Scholar, PubMed, SciELO, Scopus, and other sources, about the increasing application of UCB-SC and storage in UCB-B was done to update about all the possibilities for translational medicine. Results: We prepared a UCB overview, including the pioneering use of UCB-SC for HSC transplantation, their biological composition, characteristics, and the UC-associated tissues like Wharton-Jelly and the human term placenta, UCB advantages, and disadvantages in HSC transplantation, the number of clinical trials applying UCB donation samples, and promising possibilities for regenerative medicine. The existence of different types of UCB-Bs, and the development of new specific cellular manipulation techniques. The UCB-B regulatory framework and some ethical issues were also included in the review. Conclusions: After 30 years of UCB-B, more than 100 public UCB-Bs worldwide, with millions of UCB units donated altruistically, more than 800,000 clinical-grade products are now available: a great source of transplantable SC and other cellular material for the development of new therapies. Even though the UCB as a source of HSC for transplantation has been recently statistical ranked in third place, after HSC apheresis collected and bone marrow aspirates, until now, more than 50,000 UCB HSC allogeneic transplants (HSC-Allo-T) have been performed worldwide in both children and adults to treat many different diseases, including hematologic, metabolic, immunologic, neoplastic, and neurologic disorders. A significant effort has been focused on enhancing engraftment to reduce the risk of infection and cost. Recommendations: To that end, we must understand in detail the molecular mechanisms controlling SC self-renewal that may lead to the development of ex-vivo systems for HSCs expansion, characterize the mechanisms regulating the homing of HSC and determine the relative place of UCB HSC-Allo-T, as compared to other sources.},
 year = {2023}
}

Copy | Download

TY  - JOUR
T1  - Expanding the Abu Dhabi Bone Marrow Transplant Program (AD-BMT®) Scope with the Collection and Cryopreservation of Cord Blood Stem Cells
AU  - Rene Antonio Rivero-Jimenez
AU  - Antonio Alfonso Bencomo-Hernandez
AU  - Yandy Marx Castillo-Aleman
AU  - Fatema Mohammed Al Kaabi
AU  - Yendry Ventura-Carmenate
Y1  - 2023/05/10
PY  - 2023
N1  - https://doi.org/10.11648/j.cmr.20231202.12
DO  - 10.11648/j.cmr.20231202.12
T2  - Clinical Medicine Research
JF  - Clinical Medicine Research
JO  - Clinical Medicine Research
SP  - 30
EP  - 47
PB  - Science Publishing Group
SN  - 2326-9057
UR  - https://doi.org/10.11648/j.cmr.20231202.12
AB  - Introduction: The umbilical cord blood (UCB) is the blood from the placenta's blood vessels and the portion of the umbilical cord that remains attached to the newborn after the delivery when the cord is clamped and cut. UCB is rich in hematopoietic stem cells (HSC) and other stem cells (SC). Between 1974 and 1988, scientific knowledge and UCB application possibilities for human therapy opened a new significative era in cell therapy, using UCB HSC as an alternative source of SC for bone marrow transplant and the cure of patients with malignant hematological diseases. Objective: The possibility of having a UCB bank (UCB-B) in Abu Dhabi encouraged us to make this analysis. Method: A literature review from Google Scholar, PubMed, SciELO, Scopus, and other sources, about the increasing application of UCB-SC and storage in UCB-B was done to update about all the possibilities for translational medicine. Results: We prepared a UCB overview, including the pioneering use of UCB-SC for HSC transplantation, their biological composition, characteristics, and the UC-associated tissues like Wharton-Jelly and the human term placenta, UCB advantages, and disadvantages in HSC transplantation, the number of clinical trials applying UCB donation samples, and promising possibilities for regenerative medicine. The existence of different types of UCB-Bs, and the development of new specific cellular manipulation techniques. The UCB-B regulatory framework and some ethical issues were also included in the review. Conclusions: After 30 years of UCB-B, more than 100 public UCB-Bs worldwide, with millions of UCB units donated altruistically, more than 800,000 clinical-grade products are now available: a great source of transplantable SC and other cellular material for the development of new therapies. Even though the UCB as a source of HSC for transplantation has been recently statistical ranked in third place, after HSC apheresis collected and bone marrow aspirates, until now, more than 50,000 UCB HSC allogeneic transplants (HSC-Allo-T) have been performed worldwide in both children and adults to treat many different diseases, including hematologic, metabolic, immunologic, neoplastic, and neurologic disorders. A significant effort has been focused on enhancing engraftment to reduce the risk of infection and cost. Recommendations: To that end, we must understand in detail the molecular mechanisms controlling SC self-renewal that may lead to the development of ex-vivo systems for HSCs expansion, characterize the mechanisms regulating the homing of HSC and determine the relative place of UCB HSC-Allo-T, as compared to other sources.
VL  - 12
IS  - 2
ER  -

Copy | Download